


Radiotherapy in Ovarian Clear Cell Cancer

Mary McCormack - NCRI
GCIG Chicago 2017



Cancer Research UK and
UCL Cancer Trials Centre

ROCC Trial Design



ROCC Trial Design

- Median DFS for control arm of 5 years
- Aim to detect an improvement to 8 years
- HR = 0.625
- Power = 80%
- Two sided 5% significance level
- N = ~350
- 5 years of accrual and 3 years of follow-up

ROCC Current Status

- Joint Collaboration with Anna Tinker and Canadian colleagues
- CR UK Application Dec 2016 - Rejected
- Outline Application submitted to NIHR Health Technology Assessment Programme (HTA) on 5th April
- If invited for Full Application – committee review/outcome Nov 2017
- Translational component to identify molecular markers – pending application